The name's still the thing for biosimilars
This article was originally published in SRA
What's in a name? A lot, it seems, when it comes to the identification of biosimilar medicines. Should they have the same INN as the reference product, or a different one to help track the right drug down in the event of safety issues? You'd think the issue would have been settled by now, but like so much else in the biosimilars area, uncertainties still abound.
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.